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Guangzhou, ¥82,383(¥74,956-¥89,810) vs. ¥80,799(¥73,545-¥88,054) for Nanjing, and 
¥59,413(¥54,366-¥64,460) vs. ¥57,804(¥52,613-¥62,996) for Xi’an. The ICER of linezolid 
over vancomycin were ¥19,719(-¥143,553-¥320,980), ¥15,532(-¥185,411-¥349,693), 
¥15,904(-¥161,935-¥314,987), and ¥16,145(-¥100,738-¥234,412) per additional treat-
ment success for Beijing, Guangzhou, Nanjing, and Xi’an, respectively. Out of 10,000 
bootstrap simulations, majority cases had greater efficacies and higher costs for lin-
ezolid (in quadrant I of the E-EC plane: Beijing(64%), Guangzhou(59%), Nanjing(61%), 
Xi’an(66%)), more than one third had greater efficacies and lower costs for linezolid 
(linezolid dominated vancomycin: Beijing(33%), Guangzhou(38%), Nanjing(37%), 
Xi’an(32%)); only < 2% had greater efficacies and lower costs for vancomycin in 
all cities (vancomycin dominated linezolid). ConClusions: In this clinical trial 
population, linezolid appears to be cost-effective from Chinese payers’ perspective 
when compared to vancomycin in treating patients with nosocomial pneumonia 
caused by MRSA.
PIN100
EcoNomIc EvaluatIoN of fluoroquINoloNE-BasEd rEgImENs for thE 
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objeCtives: Respiratory fluoroquinolones are considered to be an important treat-
ment option in hospitalized adults with community-acquired pneumonia (CAP). 
We aimed to compare cost-effectiveness of sequential intravenous to oral therapy 
of CAP with moxifloxacin and levofloxacin ± beta-lactam in a multi-field Russian 
hospital. Methods: Standard search of prospective randomized clinical trials (RCT) 
was performed for the period since 1st Jan 1995 till 31st Dec 2012. RCTs quality 
was assessed by Jadad scale. Three RCTs with direct comparison of moxifloxacin 
vs. levofloxacin±ceftriaxone in adults with CAP required initial intravenous anti-
microbial therapy [Torres A. 2008, File T.M. Jr. 2001, Anzueto A. 2006] were included 
in the analysis. As similar efficacy and safety was shown between comparators a 
cost-minimisation model was applied. Original drugs’ costs were extracted from 
hospital receipt notes of three multi-field hospitals and wholesale prices data-
base (www.pharmindex.ru). Cost of therapy was calculated to respective treatment 
regiments in selected trials: moxifloxacin 400 mg QD vs. levofloxacin 500 mg QD/
BID±ceftriaxone 2 g QD for 11 days. Uncertainty was explored in a series of one- and 
two-way sensitivity analysis. Results: The respective total drug therapy costs per 
patient were as follows: € 249 for moxifloxacin vs. € 161/€ 321 for levofloxacin QD/BID 
and € 419/€ 579 for levofloxacin QD/BID+ceftriaxone. In levofloxacin monotherapy 
regimens the results were sensitive for IV therapy duration and oral/IV levofloxacin 
cost. In both levofloxacin+ceftriaxone regimens the results were insensitive to all 
variables of interest. ConClusions: Moxifloxacin is more cost effective strategy 
then levofloxacin+ceftriaxone for the treatment of hospitalized adults with CAP. The 
higher cost-effectiveness for moxifloxacin vs. levofloxacin monotherapy depends on 
IV therapy duration, levofloxacin regimen and oral/IV levofloxacin cost.
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objeCtives: Ceftobiprole is a new i.v. anti-infective, which has bactericidal activity 
against difficult to treat Gram-positive (including multidrug-resistant pneumococci 
and methicillin-resistant Staphylococcus aureus; MRSA) and Gram-negative (includ-
ing Pseudomonas aeruginosa) bacteria, which are important aetiological agents of 
nosocomial pneumonia (NP) and hospitalised community-acquired pneumonia (CAP). 
The objective of this analysis was to estimate the economic value of ceftobiprole (TID) 
compared to linezolid (BID)/ceftazidime (TID) in the treatment of hospitalised pneu-
monia patients in Scotland, when coverage of MRSA and Gram-negative pathogens, 
including P. aeruginosa,is required. Methods: A cost-minimisation analysis, includ-
ing only direct medical (drug) costs, was considered appropriate since the ceftobiprole 
phase 3 trials in NP and CAP demonstrated that ceftobiprole is non-inferior to a 
combination therapy consisting of linezolid and ceftazidime (NP) or ceftriaxone with 
or without linezolid (CAP). The base case model included drug acquisition, treatment 
duration, and administration costs. In additional scenario analyses, the cost-minimi-
sation analysis included ICU and total hospitalisation costs as well. The resource use 
data were derived from the NP trial. Results: Treatment with ceftobiprole resulted in 
a cost-saving of £258 per treated patient compared to linezolid/ceftazidime therapy. 
While no change in the drug budget is estimated, cost-savings are expected due to 
less administration time. Scenario analyses evaluated the reduction in length of ICU 
stay and overall hospital stay that will potentially lead to further cost savings for NHS 
Scotland (-£2,182 and -£904 per treated patient, respectively). ConClusions: This 
economic evaluation shows that ceftobiprole is at least a cost-neutral alternative 
to a combination of linezolid with ceftazidime and provides an effective and safe 
alternative for hospitalised pneumonia patients in Scotland.
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objeCtives: New antiretroviral drugs have a major impact on future treatment 
options for treatment-experienced HIV-patients with antiretroviral resistance. The 
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objeCtives: This systematic review aimed to assess the cost-effectiveness of rou-
tine varicella and herpes zoster vaccination in high-income countries. Methods: 
A PubMed search was performed for identifying English- and German-language 
publications on economic analysis of varicella and herpes zoster (HZ) vaccina-
tion programmes published before May 2013. A study was included if it was a full 
economic evaluation of a routine childhood or adolescent varicella vaccination 
programme and/or a HZ vaccination scheme targeting the elderly and if the study 
reported results for a high-income country as specified by the World Bank. To 
improve comparability between studies and across countries, all cost estimates 
were inflated to 2010 values applying country-specific consumer price indices and 
converted to Euros with the German level of purchasing power using purchasing 
power parities obtained from the Organisation for Economic Co-operation and 
Development. Results: After the study selection process, 37 model-based stud-
ies remained to be included in the review. Routine childhood or adolescent varicella 
vaccination was cost-effective or cost-saving from a payer perspective and always 
cost-saving from a societal perspective when ignoring a potential impact on HZ due 
to exogenous boosting. The inclusion of the impact on HZ led to net QALY losses or 
incremental cost-effectiveness ratios exceeding commonly accepted thresholds. 
Additional HZ vaccination could partially mitigate this effect. Results of the studies 
only focusing on the evaluation of HZ vaccination ranged from EUR 1,200 to 291,240 
per QALY in one study assessing multiple scenarios and from EUR 5,572 to 140,125 
per QALY across all other studies. ConClusions: While cost-effectiveness of HZ 
vaccination was strongly dependent on the age of vaccination, cost-effectiveness 
of varicella vaccination was primarily dependent on the in- or exclusion of the 
potential impact on HZ. As a consequence, clarification on the role of exogenous 
boosting is crucial for decision-making regarding varicella vaccination.
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objeCtives: Gram-positive bacteria cause clinically severe peritonitis and exit-
site infection (ESI) in patients on peritoneal dialysis (PD). Incident PD patients are 
most prone to developing ESI and peritonitis within the first year of dialysis. We 
investigated the potential costs, quality of life, and clinical outcomes of incident PD 
patients with or without regular application of mupirocin on exit-site from the per-
spective of health care provider in Hong Kong. Methods: We designed a decision 
tree to simulate potential outcomes of incident PD patients with and without regular 
application of mupirocin over a period of one year. Outcome measures included total 
direct medical cost per patient, quality-adjusted life-years (QALYs) gained and gram-
positive bacterial infection-related mortality rate. Model inputs were derived from 
literature. Sensitivity analyses evaluated the impact of uncertainty in all model vari-
ables. Results: In base-case analysis, the mupirocin group showed higher expected 
QALYs (0.6496 vs. 0.6456), lower infection-related mortality rate (0.18% vs. 1.64%) 
and lower total cost per patient (USD258 vs. USD1,661) comparing with the control 
group. Rate of gram-positive bacterial peritonitis without mupirocin and the risk of 
gram-positive bacterial peritonitis with mupirocin were identified to be potential 
influential factors. In 10,000 Monte Carlo simulations, mupirocin group was signifi-
cantly (p< 0.001) less costly, gained higher QALYs with lower mortality rate 99.9% of 
the time. ConClusions: Daily application of mupirocin at catheter exit-site during 
the first 12 months of PD seems to be cost-saving and effective in reducing mortality 
of PD-related gram-positive infections as well as improving health-related quality 
of life from the perspective of health care provider in Hong Kong.
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objeCtives: To assess the cost-effectiveness of linezolid versus vancomycin in 
the treatment of NP in four major cities (Beijing, Guangzhou, Nanjing, and Xi’an) 
in China. Methods: We conducted cost-effectiveness analyses from Chinese pay-
ers’ perspective piggybacked to a phase IV, randomized, double-blind, multicenter 
study (Wunderink et al, CID 2012) in MRSA-NP patients (microbiologic confirmed 
intent-to-treat cohort). Efficacy was measured by treatment success (defined as 
Cure+Improvement) at the end of study (i.e., 7-30 days after the end of treatment). 
Direct medical costs from four cities in China (¥, 2012) were calculated from the 
health care resource use data collected from the trial, including study medica-
tion, hospitalization, mechanical ventilation, and continuous renal replacement 
therapy. Nonparametric bootstrapping method was used to calculate confi-
dence intervals (CI) for costs, efficacy, and incremental cost-effectiveness ratios 
(ICER). Results: Data from 391 patients (186 linezolid, 205 vancomycin) were ana-
lyzed. More linezolid patients achieved treatment success vs. vancomycin patients 
[mean (95% CI)]: 55% (48.3%-61.9%) vs. 45% (38%-52.3%). The total treatment costs 
of linezolid vs. vancomycin were: ¥79,551(¥72,421-¥86,680) vs. ¥77,587(¥70,656-
¥84,519) for Beijing, ¥90,995(¥82,598-¥99,393) vs. ¥89,448(¥81,295-¥97,601) for 
